{"url_path":"/sec/cccc/8-k/2026-06-24/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1662579/0001628280-26-045194-index.html","accession_number":"0001628280-26-045194","cik":"0001662579","ticker":"CCCC","issuer_name":"C4 Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1662579/0001628280-26-045194-index.html","primary_entity_key":"0001662579","primary_entity_name":"C4 Therapeutics, Inc."},"word_count":138,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.\n\nExhibit\n\nNumber\n\nDescription\n\n10.1#\n\n[Amendment No. 2 to the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan](c4t-amendment2to2020stoc.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n# Indicates a management contract or any compensatory plan, contract or arrangement.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nC4 Therapeutics, Inc.\n\nDate: June 24, 2026\n\nBy:\n\n/s/ Kendra R. Adams\n\nKendra R. Adams\n\nChief Financial Officer and Treasurer"}